A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction

作者：Takagi Hisato^*; Mizuno Yusuke; Niwa Masao; Goto Shin nosuke; Umemoto Takuya

来源：Hypertension Research, 2014, 37(5): 432-437.

DOI：10.1038/hr.2013.142

• azilsartan
• meta-analysis
• randomized controlled trial

Although there have been a number of azilsartan trials, no meta-analysis of the findings has been conducted to date. We performed the first meta-analysis of randomized controlled trials of azilsartan therapy for the reduction of blood pressure (BP) in patients with hypertension. MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials were searched from the beginning of the records through March 2013 using web-based search engines (PubMed and OVID). Eligible studies were prospective randomized controlled trials of azilsartan (including azilsartan medoxomil) vs. any control therapy that reported clinic or 24-h mean BP as an outcome. For each study, data for the changes from baseline to final clinic systolic BP (SBP) and diastolic BP (DBP) in both the azilsartan group and the control group were used to generate mean differences and 95% confidence intervals (CIs). Of 27 potentially relevant articles screened initially, 7 reports of randomized trials of azilsartan or azilsartan medoxomil therapy enrolling a total of 6152 patients with hypertension were identified and included. Pooled analysis suggested a significant reduction in BP changes among patients randomized to 40 mg of azilsartan vs. control therapy (clinic SBP: -4.20mmHg; 95% CI: -6.05 to -2.35mmHg; P<0.00001; clinic DBP: -2.58mmHg; 95% CI: -3.69 to -1.48mmHg; P<0.00001; 24-h mean SBP: -3.33mmHg; 95% CI: -4.74 to -1.93mmHg; P<0.00001; 24-h mean DBP: -2.12mmHg; 95% CI: -2.74 to -1.49mmHg; P<0.00001). In conclusion, azilsartan therapy appears to provide a greater reduction in BP than control therapy in patients with hypertension.

• 出版日期2014-5